A federal jury in Louisiana found that Janssen Pharmaceuticals Inc. and Bayer Corp., makers of blood thinner Xarelto, adequately warned about the risk of unstoppable bleeding and that it did not cause the plaintiff to suffer a stroke that killed her.
The case was Joseph Orr Jr. v. Janssen Pharmaceuticals, Inc., et al., No. 15-3708, E.D. LA. Some 17,097 cases are pending before US District Judge Eldon E. Fallon in MDL 2592, IN RE: Xarelto (Rivaroxaban) Products Liability Litigation.
It was a weak case to begin with. The plaintiff Sharyn Orr, was a 67-year-old grandmother who had a host of medical problems. See No Cause for Panic in Defense Verdict in the First Xarelto Bellwether Trial.
The jury returned itsverdict on June 12 in the second bellwether trial in the Xarelto multidistrict litigation.
Plaintiff Sharyn Orr took Xarelto to prevent blood clots due to atrial fibrillation. She died after suffering a stroke in 2015. Her husband and children filed the acting, charging that Janssen and Bayer failed to adequately warn that it could cause uncontrolled brain bleeding.
The manufacturers argued successfully that the Xarelto label sufficiently addressed the risk of uncontrolled bleeding.
The plaintiff attorneys were Thomas C. Wicker III, James A. Watkins and Vincent E. Odom of Capitelli & Wicker in New Orleans and Albert J. Nicaud of Nicaud & Sunseri in Metairie, Louisiana.
Bayer is represented by Susan M. Sharko, an attorney with Drinker, Biddle & Reath in Florham Park, N.J.